​

Exhibit 10.1

​

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER IDENTIFIED BY THE MARK “[***]”.

EXCLUSIVE LICENSE AGREEMENT

for MSK’s Technology

[***]

TABLE OF CONTENTS

PREAMBLE ARTICLES:	​ ​ ​	​
1.	​	DEFINITIONS
2.	​	GRANT
3.	​	SUBLICENSES
4.	​	DILIGENCE
5.	​	CONSIDERATION
6.	​	REPORTS AND RECORDS
7.	​	PATENT PREPARATION, FILING, PROSECUTION, AND MAINTENANCE
8.	​	PATENT ENFORCEMENT
9.	​	CONFIDENTIALITY
10.	​	INDEMNIFICATION AND INSURANCE

…

INDEMNITY AGREEMENT

THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of [●], by and between CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and [●] (“Indemnitee”).

RECITALS

WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors, officers or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of such corporations;

WHEREAS, the Board of Directors of the Company (the “Board”) has determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company and its subsidiaries from certain liabilities. Although the furnishing of such insurance has been a customary and widespread practice among United States-based corporations and other business enterprises, the Company believes that, given current market conditions and trends, such insurance may be available to it in the future only at higher premiums and with more exclusions. At the same time, directors, officers and other persons in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming litigation relating to, among other things, matters that traditionally would have been brought only against the Company or business enterprise

…

May 13, 2026

***BY EMAIL ***

Christopher Downs

RE:   Separation from CNS Pharmaceuticals, Inc.

** **

Dear Christopher,

As you are aware, CNS Pharmaceuticals, Inc. (the “Company”) has made the difficult decision to terminate your employment, effective as of May 13, 2026 (the “Separation Date”). You will receive your final paycheck within the time required by law. Please submit a request for reimbursement and supporting documentation within seven (7) days of the Separation Date for all unpaid business expenses incurred prior to the Separation Date. The Company shall reimburse you for such expenses consistent with Company policy.

In consideration for your execution of this Agreement (this “Agreement”) and the mutual exchange of other promises, the receipt and sufficiency of which are hereby acknowledged, the Company is offering to provide you with certain severance benefits, described below.

1.Severance Benefits. Subject to your timely execution, return, and non-revocation of this Agreement and your continuing compliance with Sections 4, 5 and 15 below, the Company is offering you the following benefits (collectively, the “Severance Benefits”):

** **

…

Xilio Therapeutics, Inc.

THIRD AMENDED AND RESTATED

2022 INDUCEMENT STOCK INCENTIVE PLAN

1.

Purpose

The purpose of this Second Amended and Restated 2022 Inducement Stock Incentive Plan (the “Plan”) of Xilio Therapeutics, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company with an inducement material for such persons to enter into employment with the Company and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests of such persons with those of the Company’s stockholders. Except where the context otherwise requires, the term “Company” shall include any of the Company’s present or future parent or subsidiary corporations as defined in Sections 424(e) or (f) of the Internal Revenue Code of 1986, as amended, and any regulations thereunder (the “Code”) and any other business venture (including, without limitation, joint venture or limited liability company) in which the Company has a controlling interest, as determined by the Board of Directors of the Company (the “Board”).

2.

Eligibility

…

May 18, 2026

Totalstone, LLC

Northeast Masonry Distributors, LLC

Totalstone Properties, LLC

1 Red Valley Rd.

Millstone Township, NJ 08510

Attn: Matthew Lipman, Manager

CS Purchase Holdings LLC

Carolina Stone Holdings, LLC

2140 South DuPont Hwy

Camden, DE 19934

Attn: Matthew Lipman, Manager

Carolina Stone Distributors, LLC

10312 Globe Rd.

Morrisville, NC 27560

Attn: Matthew Lipman, Manager

	Re:	**Waiver Request Under the Fifteenth Amendment to Revolving Credit, Term Loan and Security Agreement **

Dear Mr. Lipman:

Reference is made to certain (i) Revolving Credit, Term Loan and Security Agreement (the “Original Loan Agreement”) dated as of December 20, 2017 by and among TotalStone, LLC, a Delaware limited liability company (“TotalStone”) and Beacon Bank & Trust (successor by merger to Berkshire Bank), a Massachusetts chartered trust company (“Lender”), (ii) that certain Fifteenth Amendment to Revolving Credit, Term Loan And Security Agreement (“Fifteenth Amendment”; the Fifteenth Amendment, the Original Loan Agreement and all other amendments to the Original Loan Agreement and subsequent amendments are collectively referred to as the “Loan Agreement”) dated as of December 19, 2025, by and among TotalStone, Northeast Masonry Distributors, LLC (f/k/a NEM Purchaser, LLC), a Delaware limited liability company

…

ARBUTUS BIOPHARMA CORPORATION 2026 OMNIBUS SHARE AND INCENTIVE PLAN RESTRICTED SHARE UNIT AGREEMENT (U.S.) COVER SHEET Arbutus Biopharma Corporation, a company incorporated under the laws of the Province of British Columbia (the “Company”), hereby grants restricted share units (the “RSUs”) relating to the Company’s common shares, without par value (the “Common Shares”), to the Grantee named below, subject to the vesting and other conditions set forth below. Additional terms and conditions of the RSUs are set forth in this cover sheet and in the attached Restricted Share Unit Agreement (together, the “Agreement”) and in the Arbutus Biopharma Corporation 2026 Omnibus Share and Incentive Plan (as it has been or may be amended and/or restated from time to time, the “Plan”). Name of Grantee: [●] Grant Date: [●] Number of Common Shares Covered by the RSUs: [●] Vesting Commencement Date: [●] Vesting Schedule: [●] By your electronic acknowledgement of this Agreement, you agree to all of the terms and conditions described in the Agreement and in the Plan (a copy of which has been made available to you and will be provided on request). You acknowledge that you have carefully reviewed the Plan and agree that the Plan shall control in the event any provision of this Agreement should appear to be inconsistent with the Plan. Grantee: Date: (Signature) Company: Date: (Signature) Name: Title:

---

Attachment This is not a share certificate or a negotiable instrument.

---

…

ARBUTUS BIOPHARMA CORPORATION 2026 OMNIBUS SHARE AND INCENTIVE PLAN INCENTIVE STOCK OPTION AGREEMENT COVER SHEET Arbutus Biopharma Corporation, a company incorporated under the laws of the Province of British Columbia (the “Company”), hereby grants an option (the “Option”) to purchase the Company’s common shares, without par value (the “Common Shares”), to the Grantee named below, subject to the vesting and other conditions set forth below. Additional terms and conditions of the Option are set forth in this cover sheet and in the attached Incentive Stock Option Agreement (together, the “Agreement”) and in the Arbutus Biopharma Corporation 2026 Omnibus Share and Incentive Plan (as it has been or may be amended and/or restated from time to time, the “Plan”). Name of Grantee: [●] Grant Date: [●] Number of Common Shares Covered by the Option: [●] Option Price per Common Share: [●] Vesting Commencement Date: [●] Vesting Schedule: The Option shall vest as follows: one third to vest on [INSERT DATE]; one third to vest on [INSERT DATE] and one third to vest on [INSERT DATE], while the Grantee remains an eligible Service Provider, and will be exercisable in whole up to the expiration of the Option or such earlier date as may be required or stipulated in accordance with the Plan or the terms of this Agreement; the Option, once vested, shall remain vested until the expiration, termination or surrender of the Option. By your electronic acknowledgement of this Agreement, you agree to all of the terms and conditions described in the Agreement and in the Plan (a copy of which has

…

August 10, 2026

3i, LP
2 Wooster Street, 2nd Floor
New York, New York 10013
Attn: Maier J. Tarlow

Re: Conversion Price Voluntary Adjustment Notice

Dear Sirs:

Reference is made to (a) that certain Securities Purchase Agreement dated as of July 29, 2025 (the “Purchase Agreement”) between Capstone Holding Corp. (the “Company”) and 3i, LP (the “Investor”), (b) the senior secured convertible notes of the Company, each with a 8.34% original issue discount, issued to the Investor on July 29, 2025 (as amended, including pursuant to that certain First Amendment thereto) and October 22, 2025 (each, a “Note” and together, the “Notes”), and (c) the other transaction documents, as modified from time to time, referred to collectively, as the “Transaction Documents”. Capitalized terms used but not defined herein shall have the meanings given to them in the Purchase Agreement, or if not defined therein, in the applicable Note, or if not defined therein, in the applicable Transaction Document, in each case as of the date hereof.

This letter agreement (this “Letter Agreement”) confirms our recent discussions about, among other matters, certain modifications to the Notes.

…

CAPSTONE HOLDING CORP.

2025 Stock Incentive Plan

Master Restricted Stock Agreement

Capstone Holding Corp. (the “Company”) and the Recipient named below each hereby into this Master Restricted Stock Agreement on the execution date specified in the table below (including the Terms and Conditions attached hereto, the “Agreement”). The Company grants to the Recipient the shares of Restricted Stock specified herein on the dates specified herein pursuant to the Capstone Holding Corp. 2025 Stock Incentive Plan, as amended and in effect from time to time (the “Plan”).

Name of recipient (the “Recipient”):	Matthew Lipman
Reference Date	June 30, 2026

…

CAPSTONE HOLDING CORP.

2025 Stock Incentive Plan

Master Restricted Stock Agreement

Capstone Holding Corp. (the “Company”) and the Recipient named below each hereby into this Master Restricted Stock Agreement on the execution date specified in the table below (including the Terms and Conditions attached hereto, the “Agreement”). The Company grants to the Recipient the shares of Restricted Stock specified herein on the dates specified herein pursuant to the Capstone Holding Corp. 2025 Stock Incentive Plan, as amended and in effect from time to time (the “Plan”).

Name of recipient (the “Recipient”):
Reference Date	June 30, 2026

…

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

Center for Technology Licensing

1155 York Avenue New York, NY 10065 P: 646.962.7045

innovation.weill.cornell.edu

Weill Cornell Medicine Enterprise Innovation

April 28, 2026

[***]

RE: THIRD AMENDMENT

to the THIRD LICENSE AGREEMENT by and between Lexeo Therapeutics, Inc. (hereinafter “Licensee”) and Cornell University (“Cornell”) (each a “Party”) effective April 21, 2024, amended a first time effective May 24, 2024, and amended a second time effective December 22, 2025 (the “Third License Agreement”) (CTL Contract No. [***])

WHEREAS, Section 1 of the Second Amendment to this Agreement (effective December 22, 2025) refers to "Paragraph 3.1" being deleted and replaced; the Parties acknowledge that this reference was a scrivener's error, and that the Parties intended to delete and replace only Paragraph 3.1(a);

Effective the date of the last signature hereto (“Third Amendment Date”), the Parties agree to hereby modify the Third License Agreement as follows:

1)

Section 1 of the Second Amendment to this Agreement (effective December 22, 2025) contained a scrivener’s error. The reference to “Paragraph 3.1” in Section 1 of the Second Amendment is hereby corrected to read “Paragraph 3.1(a).” As corrected, Section 1 of the Second Amendment reads in its entirety as follows:

…

​

THIRD AMENDMENT TO

NOTE PURCHASE AGREEMENT

This THIRD AMENDMENT TO NOTE PURCHASE AGREEMENT, dated as of June 29, 2026 (this “Amendment”), is made by and among Milestone Pharmaceuticals Inc., a corporation existing under the Business Corporations Act (Québec) (the “Company”), the Purchasers (defined below), RTW Investments, LP, as agent for the Purchasers (in such capacity, the “Principal Purchaser”). Capitalized terms used herein, but not otherwise defined herein, shall have the respective meanings set forth in the Note Purchase Agreement (defined below).

WITNESSETH:

WHEREAS, the Company entered into the Note Purchase Agreement, dated as of March 27, 2023, as amended by the First Amendment to Note Purchase Agreement, dated as of August 4, 2023 and the Second Amendment to Note Purchase Agreement, dated as of January 12, 2026 (as amended, the “Note Purchase Agreement”), with the purchasers from time to time party thereto (each, a “Purchaser,” and collectively, the “Purchasers”), the Principal Purchaser, and Acquiom Agency Services LLC, as collateral agent for the Purchasers, pursuant to which the Company has issued $50,000,000 aggregate principal amount of its 6.0% Convertible Senior Secured Notes due March 31, 2029 (each as amended, restated, supplemented or otherwise modified from time to time, the “Notes”); and

…